Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.06 USD
Change Today +0.85 / 26.48%
Volume 568.0K
CDXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 3:44 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Key Developments

Codexis, Inc. - Special Call

Codexis, Inc. - Special Call

Codexis, Inc. Enters into CodeEvolver® Platform Technology License Agreement with Merck

Codexis, Inc. announced the signing of a CodeEvolver® platform technology license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. This transaction marks the second CodeEvolver licensing agreement between Codexis and a major pharmaceutical company and advances the technology's business model of multiple sources of revenue. Under the terms of the agreement, Codexis has granted Merck a non-exclusive license to use Codexis' proprietary CodeEvolver protein engineering platform technology to develop novel enzymes for use in the manufacture of Merck's pharmaceutical products. Upon completion of the technology transfer, a Codexis' CodeEvolver protein engineering platform will be located at a Merck research site. Codexis is eligible to receive up to $18 million over approximately the next 15 to 24 months, $5 million of which will be paid upon the signing of this agreement and an additional $13 million subject to the satisfactory completion of certain technology transfer milestones. Codexis will also be eligible to receive payments of up to maximum of $15 million for each pharmaceutical ingredient (API) using novel enzymes developed by Merck using the CodeEvolver technology and used for commercial manufacturing purposes.

Codexis, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second Half and Year 2015

Codexis, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company reported total revenues of $6,798,000 against $7,074,000 a year ago. Loss from operations was $5,529,000 against $6,396,000 a year ago. Loss before income taxes was $5,550,000 against $6,505,000 a year ago. Net loss was $5,562,000 or $0.14 per basic and diluted share against $6,375,000 or $0.17 per basic and diluted share a year ago. Net loss - Non-GAAP was $2,875,000 or $0.07 per basic and diluted share against $4,046,000 or $0.11 per basic and diluted share a year ago. The company affirmed its financial guidance for 2015. For the period, the company expects total revenues of $39 million to $42 million, representing growth of 10% to 19% over 2014. This revenue guidance assumes recognizing a $6.5 million milestone related to the company's non-exclusive licensing agreement with GSK, which is expected toward the end of 2015. Gross margins as a percent of total revenue are expected to be in the range of 70% to 75%. The company expects stronger growth in the second half of 2015 compared with the first half.

Codexis, Inc., Annual General Meeting, Jun 10, 2015

Codexis, Inc., Annual General Meeting, Jun 10, 2015., at 09:00 Pacific Standard Time. Location: executive offices at 400 Penobscot Drive. Agenda: To elect each of Kathleen S. Glaub, Bernard J. Kelley and John J. Nicols to board of directors for a three-year term expiring at the 2018 annual meeting of stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal; to ratify the selection of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly come before the annual meeting.

Codexis, Inc. to Report Q1, 2015 Results on May 07, 2015

Codexis, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $4.06 USD +0.85

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €79.49 EUR +0.51
Cambrex Corp $52.07 USD +2.35
Koninklijke DSM NV €52.25 EUR -0.26
Novozymes A/S kr361.70 DKK +2.50
Takasago International Corp ¥625.00 JPY +11.00
View Industry Companies
 

Industry Analysis

CDXS

Industry Average

Valuation CDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.